MDGL
Madrigal Pharmaceuticals, Inc.
Biotechnology
Market Cap$12.38B
5Y Perf.+365.2%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
MDGL vs ELVN
Revenue, margins, valuation, and 5-year total return — side by side.
ELVN
Enliven Therapeutics, Inc.
Biotechnology
Market Cap$2.45B
5Y Perf.-69.2%
MDGL vs ELVN — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | MDGL | ELVN |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $12.38B | $2.45B |
| Revenue (TTM) | $1.13B | $0.00 |
| Net Income (TTM) | $-309M | $-104M |
| Gross Margin | 93.1% | — |
| Operating Margin | -27.7% | — |
| Total Debt | $354M | $0.00 |
| Cash & Equiv. | $199M | $99M |
MDGL vs ELVN — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
MDGL
ELVN
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Madrigal Pharmaceut… (MDGL) | 100 | 465.2 | +365.2% |
| Enliven Therapeutic… (ELVN) | 100 | 30.8 | -69.2% |
Price return only. Dividends and distributions are not included.
Quick Verdict: MDGL vs ELVN
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: ELVN leads in 3 of 6 categories, making it the strongest pick for profitability and margin quality and recent price momentum and sentiment. Madrigal Pharmaceuticals, Inc. is the stronger pick specifically for growth and revenue expansion and capital preservation and lower volatility. As sector peers, any of these can serve as alternatives in the same allocation.
MDGL
Madrigal Pharmaceuticals, Inc.
The Income Pick
MDGL is the clearest fit if your priority is income & stability and growth exposure.
- Dividend streak 1 yrs, beta 0.57
- Rev growth 432.1%, EPS growth 41.3%
- 37.6% 10Y total return vs ELVN's -31.3%
Best for: income & stability and growth exposure
ELVN
Enliven Therapeutics, Inc.
The Quality Compounder
ELVN carries the broadest edge in this set and is the clearest fit for quality and momentum.
- 3.4% margin vs MDGL's -27.3%
- +109.2% vs MDGL's +82.9%
- -23.4% ROA vs MDGL's -25.4%, ROIC -32.8% vs -29.4%
Best for: quality and momentum
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | MDGL | 432.1% revenue growth vs ELVN's -16.6% |
| Quality / Margins | ELVN | 3.4% margin vs MDGL's -27.3% |
| Stability / Safety | MDGL | Beta 0.57 vs ELVN's 1.27 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | ELVN | +109.2% vs MDGL's +82.9% |
| Efficiency (ROA) | ELVN | -23.4% ROA vs MDGL's -25.4%, ROIC -32.8% vs -29.4% |
MDGL vs ELVN — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2025
Segment breakdown not available.
MDGL vs ELVN — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLELVNLAGGINGMDGL
MDGLMadrigal Pharmaceutic…
1leads
ELVNEnliven Therapeutics,…
3leads
6 Total Categories
CATEGORYLEADERvs MDGLMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
ELVN1/1
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
ELVN5/6
Total Returns1Y, 3Y, 5Y total returns with dividends
ELVN4/6
Risk & VolatilityBeta, volatility, and downside exposure
MDGL2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
ELVN leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
MDGL and ELVN operate at a comparable scale, with $1.1B and $0 in trailing revenue.
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| RevenueTrailing 12 months | $1.1B | $0 |
| EBITDAEarnings before interest/tax | -$312M | -$119M |
| Net IncomeAfter-tax profit | -$309M | -$104M |
| Free Cash FlowCash after capex | -$272M | -$70M |
| Gross MarginGross profit ÷ Revenue | +93.1% | — |
| Operating MarginEBIT ÷ Revenue | -27.7% | — |
| Net MarginNet income ÷ Revenue | -27.3% | — |
| FCF MarginFCF ÷ Revenue | -24.1% | — |
| Rev. Growth (YoY)Latest quarter vs prior year | +126.8% | — |
| EPS Growth (YoY)Latest quarter vs prior year | +2.1% | +2.2% |
ELVN leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
Evenly matched — MDGL and ELVN each lead in 1 of 2 comparable metrics.
Valuation Metrics
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| Market CapShares × price | $12.4B | $2.4B |
| Enterprise ValueMkt cap + debt − cash | $12.5B | $2.4B |
| Trailing P/EPrice ÷ TTM EPS | -42.00x | -22.51x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 12.92x | — |
| Price / BookPrice ÷ Book value/share | 20.09x | 5.08x |
| Price / FCFMarket cap ÷ FCF | — | — |
Evenly matched — MDGL and ELVN each lead in 1 of 2 comparable metrics.
Profitability & Efficiency
ELVN leads this category, winning 5 of 6 comparable metrics.
Profitability & Efficiency
ELVN delivers a -24.2% return on equity — every $100 of shareholder capital generates $-24 in annual profit, vs $-50 for MDGL.
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| ROE (TTM)Return on equity | -50.2% | -24.2% |
| ROA (TTM)Return on assets | -25.4% | -23.4% |
| ROICReturn on invested capital | -29.4% | -32.8% |
| ROCEReturn on capital employed | -32.9% | -31.1% |
| Piotroski ScoreFundamental quality 0–9 | 3 | 3 |
| Debt / EquityFinancial leverage | 0.59x | — |
| Net DebtTotal debt minus cash | $156M | -$99M |
| Cash & Equiv.Liquid assets | $199M | $99M |
| Total DebtShort + long-term debt | $354M | $0 |
| Interest CoverageEBIT ÷ Interest expense | -17.51x | — |
ELVN leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
ELVN leads this category, winning 4 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in MDGL five years ago would be worth $42,596 today (with dividends reinvested), compared to $14,487 for ELVN. Over the past 12 months, ELVN leads with a +109.2% total return vs MDGL's +82.9%. The 3-year compound annual growth rate (CAGR) favors ELVN at 29.1% vs MDGL's 20.4% — a key indicator of consistent wealth creation.
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| YTD ReturnYear-to-date | -9.1% | +165.1% |
| 1-Year ReturnPast 12 months | +82.9% | +109.2% |
| 3-Year ReturnCumulative with dividends | +74.7% | +115.3% |
| 5-Year ReturnCumulative with dividends | +326.0% | +44.9% |
| 10-Year ReturnCumulative with dividends | +3755.2% | -31.3% |
| CAGR (3Y)Annualised 3-year return | +20.4% | +29.1% |
ELVN leads this category, winning 4 of 6 comparable metrics.
Risk & Volatility
MDGL leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
MDGL is the less volatile stock with a 0.57 beta — it tends to amplify market swings less than ELVN's 1.27 beta. A beta below 1.0 means the stock typically moves less than the S&P 500.
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.57x | 1.27x |
| 52-Week HighHighest price in past year | $615.00 | $48.50 |
| 52-Week LowLowest price in past year | $265.00 | $14.79 |
| % of 52W HighCurrent price vs 52-week peak | +87.8% | +84.9% |
| RSI (14)Momentum oscillator 0–100 | 45.5 | 51.1 |
| Avg Volume (50D)Average daily shares traded | 312K | 1.1M |
MDGL leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Wall Street rates MDGL as "Buy" and ELVN as "Buy". Consensus price targets imply 30.7% upside for MDGL (target: $706) vs 5.2% for ELVN (target: $43).
| Metric | MDGLMadrigal Pharmace… | ELVNEnliven Therapeut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $705.67 | $43.33 |
| # AnalystsCovering analysts | 23 | 6 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | 1 | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | +0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
ELVN leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). MDGL leads in 1 (Risk & Volatility). 1 tied.
Best OverallEnliven Therapeutics, Inc. (ELVN)Leads 3 of 6 categories
Loading custom metrics...
MDGL vs ELVN: Frequently Asked Questions
8 questions · data-driven answers · updated daily
01Is MDGL or ELVN a better buy right now?
Analysts rate Madrigal Pharmaceuticals, Inc.
(MDGL) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — MDGL or ELVN?
Over the past 5 years, Madrigal Pharmaceuticals, Inc.
(MDGL) delivered a total return of +326. 0%, compared to +44. 9% for Enliven Therapeutics, Inc. (ELVN). Over 10 years, the gap is even starker: MDGL returned +37. 6% versus ELVN's -31. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — MDGL or ELVN?
By beta (market sensitivity over 5 years), Madrigal Pharmaceuticals, Inc.
(MDGL) is the lower-risk stock at 0. 57β versus Enliven Therapeutics, Inc. 's 1. 27β — meaning ELVN is approximately 125% more volatile than MDGL relative to the S&P 500.
04Which is growing faster — MDGL or ELVN?
On earnings-per-share growth, the picture is similar: Madrigal Pharmaceuticals, Inc.
grew EPS 41. 3% year-over-year, compared to 3. 2% for Enliven Therapeutics, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — MDGL or ELVN?
Enliven Therapeutics, Inc.
(ELVN) is the more profitable company, earning 0. 0% net margin versus -30. 1% for Madrigal Pharmaceuticals, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ELVN leads at 0. 0% versus -31. 3% for MDGL. At the gross margin level — before operating expenses — MDGL leads at 94. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Which pays a better dividend — MDGL or ELVN?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
07Is MDGL or ELVN better for a retirement portfolio?
For long-horizon retirement investors, Madrigal Pharmaceuticals, Inc.
(MDGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57)). Both have compounded well over 10 years (MDGL: +37. 6%, ELVN: -31. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
08What are the main differences between MDGL and ELVN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: MDGL is a mid-cap high-growth stock; ELVN is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.